(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are AMC, Aprea Therapeutics, and BeiGene.

The three biggest losers today are AGBA Acquisition Limited, Adial Pharmaceuticals, and Travelzoo.

Winners today

1. AMC (AMC) – 20.99%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. As of March 1, 2022, it operated approximately 950 theatres and 10,600 screens. The company was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC jumping 20.99% to $4.90 on Friday, after four successive sessions in a row of gains. NYSE rose 0.07% to $15,379.13, after two successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-39.152.

Previous days news about AMC

• : AMC ‘continuing to evaluate next steps’ as judge denies request for quicker stock conversion. According to MarketWatch on Thursday, 6 April, "AMC Entertainment Holdings Inc. said Thursday that it’s "continuing to evaluate next steps" after a judge into regular AMC shares, and while the two sides asked a judge to lift the status-quo order holding up the conversion, the judge said Wednesday that the parties "offer no good cause to lift" the order. ", "Unless and until the Court lifts the Status Quo Order," AMC "will not proceed with filing the amendment to the company’s certificate of incorporation to effect the share increase and the reverse stock split previously approved by stockholders or the conversion of AMC Preferred Equity Units (APEs) into Class A common stock," the company said in a Thursday filing with the Securities and Exchange Commission. "
• AMC entertainment stock news: court dismisses APE conversion. According to FXStreet on Thursday, 6 April, "That was when AMC said in a filing that it had agreed to a settlement with the litigants. ", "Now, however, the Delaware Court of Chancery has halted the settlement that would have set up AMC to sell further equity and then pay off more of its heavy debt load."

More news about AMC.

2. Aprea Therapeutics (APRE) – 15.1%

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Aprea Therapeutics rising 15.1% to $4.42 on Friday, following the last session’s upward trend. NASDAQ jumped 0.76% to $12,087.96, after three successive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Aprea Therapeutics has a trailing twelve months EPS of $-71.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -294.69%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 79.2% and 98%, respectively.

Moving Average

Aprea Therapeutics’s worth is way below its 50-day moving average of $6.28 and way under its 200-day moving average of $11.91.

Volume

Today’s last reported volume for Aprea Therapeutics is 62409 which is 264.83% above its average volume of 17106.

More news about Aprea Therapeutics.

3. BeiGene (BGNE) – 12.48%

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with BeiGene jumping 12.48% to $238.45 on Friday while NASDAQ jumped 0.76% to $12,087.96.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-19.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.54%.

More news about BeiGene.

4. VBI Vaccines (VBIV) – 12.12%

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. The company primarily serves physicians and pharmacists through direct sales. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition For Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with VBI Vaccines jumping 12.12% to $0.14 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, VBI Vaccines has a trailing twelve months EPS of $-0.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -108.92%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

VBI Vaccines’s EBITDA is -3.7.

Sales Growth

VBI Vaccines’s sales growth is 550.8% for the ongoing quarter and 322% for the next.

Volume

Today’s last reported volume for VBI Vaccines is 10108100 which is 672.91% above its average volume of 1307790.

Moving Average

VBI Vaccines’s worth is way below its 50-day moving average of $0.43 and way under its 200-day moving average of $0.65.

Previous days news about VBI Vaccines

• VBI vaccines (vbiv) down 53% on initiating restructuring plans. According to Zacks on Wednesday, 5 April, "Shares of VBI Vaccines (VBIV Quick QuoteVBIV – Free Report) plummeted 53.1% on Apr 4 after management announced multiple restructuring initiatives to curb cash burn and save operating expenses.", "This reverse stock split is intended to allow VBI Vaccines to regain compliance with NASDAQ’s continued listing requirements."

More news about VBI Vaccines.

5. Novavax (NVAX) – 11.46%

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax jumping 11.46% to $8.46 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-7.27.

Volume

Today’s last reported volume for Novavax is 7432490 which is 16.46% above its average volume of 6381930.

Moving Average

Novavax’s worth is below its 50-day moving average of $8.59 and way under its 200-day moving average of $24.87.

More news about Novavax.

6. Inovio Pharmaceuticals (INO) – 10.38%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals rising 10.38% to $0.77 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-1.073.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -92.27%.

Volume

Today’s last reported volume for Inovio Pharmaceuticals is 8468610 which is 75.37% above its average volume of 4828980.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3038.2%, now sitting on 10.98M for the twelve trailing months.

More news about Inovio Pharmaceuticals.

7. XTL Biopharmaceuticals Ltd. (XTLB) – 10.31%

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

NASDAQ ended the session with XTL Biopharmaceuticals Ltd. rising 10.31% to $1.27 on Friday, following the last session’s upward trend. NASDAQ jumped 0.76% to $12,087.96, after three consecutive sessions in a row of losses, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, XTL Biopharmaceuticals Ltd. has a trailing twelve months EPS of $-0.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.89%.

Moving Average

XTL Biopharmaceuticals Ltd.’s worth is below its 50-day moving average of $1.29 and under its 200-day moving average of $1.38.

Yearly Top and Bottom Value

XTL Biopharmaceuticals Ltd.’s stock is valued at $1.27 at 17:32 EST, way under its 52-week high of $2.47 and way higher than its 52-week low of $0.85.

More news about XTL Biopharmaceuticals Ltd..

8. Aileron Therapeutics (ALRN) – 10%

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

NASDAQ ended the session with Aileron Therapeutics jumping 10% to $1.32 on Friday while NASDAQ jumped 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Aileron Therapeutics has a trailing twelve months EPS of $-6.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -87.42%.

More news about Aileron Therapeutics.

9. Akoustis Technologies (AKTS) – 9.61%

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.

NASDAQ ended the session with Akoustis Technologies jumping 9.61% to $3.08 on Friday while NASDAQ jumped 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Akoustis Technologies has a trailing twelve months EPS of $-1.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.51%.

Volume

Today’s last reported volume for Akoustis Technologies is 724492 which is 12.31% below its average volume of 826209.

More news about Akoustis Technologies.

10. Ebix (EBIX) – 8.84%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, and healthcare industries in the United States and internationally. It develops and deploys insurance and reinsurance exchanges; provides software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, and front-end and back-end systems; and offers outsourced administrative and risk compliance solutions. The company operates P&C exchanges primarily in Australia, New Zealand, the United Kingdom, and the United States, which facilitates the exchange of insurance data between brokers and insurance carriers with a focus on the areas of personal and commercial lines. Its exchange related products and services include travel exchanges and money transfer services; foreign exchange and outward remittance services; payment services; gift cards for consumers that can be redeemed at various merchants; and technology services for various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setting up, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services comprising project management and development; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix rising 8.84% to $13.05 on Friday while NASDAQ jumped 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $3.02.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 4.32. Meaning, the purchaser of the share is investing $4.32 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.42%.

Volume

Today’s last reported volume for Ebix is 735431 which is 88.69% above its average volume of 389740.

Volatility

Ebix’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.21%, a negative 0.92%, and a positive 3.22%.

Ebix’s highest amplitude of average volatility was 4.63% (last week), 3.37% (last month), and 3.22% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 34.5%, now sitting on 1.06B for the twelve trailing months.

More news about Ebix.

Losers Today

1. AGBA Acquisition Limited (AGBAW) – -43.78%

AGBA Group Holding Limited focuses on operating a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company offers a range of financial products, such as life insurance, pensions, property-casualty insurance, mutual funds, money lending, and real estate agency services. It also operates an health and wealth management platform that offers a range of services and value-added information in health, insurance, investments, and social sharing. The company is based in Wan Chai, Wan Chai.

NASDAQ ended the session with AGBA Acquisition Limited dropping 43.78% to $0.02 on Friday while NASDAQ rose 0.76% to $12,087.96.

Yearly Top and Bottom Value

AGBA Acquisition Limited’s stock is valued at $0.02 at 17:32 EST, below its 52-week low of $0.02.

More news about AGBA Acquisition Limited.

2. Adial Pharmaceuticals (ADILW) – -18.8%

NASDAQ ended the session with Adial Pharmaceuticals dropping 18.8% to $0.04 on Friday while NASDAQ rose 0.76% to $12,087.96.

More news about Adial Pharmaceuticals.

3. Travelzoo (TZOO) – -12.69%

Travelzoo, an Internet media company, provides travel, entertainment, and local deals from travel and entertainment companies, and local businesses in the Asia Pacific, Europe, and North America. Its publications and products include Travelzoo Website; Travelzoo iPhone and Android apps; Travelzoo Top 20 email newsletter; and Newsflash email alert service. The company also operates the Travelzoo Network, a network of third-party Websites that list travel deals published by the company; and Local Deals and Getaway listings, which allow its members to purchase vouchers for deals from local businesses, such as spas, hotels, and restaurants. It serves airlines, hotels, cruise lines, vacations packagers, tour operators, destinations, car rental companies, travel agents, theater and performing arts groups, restaurants, spas, and activity companies. Travelzoo Inc. was founded in 1998 and is headquartered in New York, New York.

NASDAQ ended the session with Travelzoo falling 12.69% to $5.64 on Friday while NASDAQ jumped 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Travelzoo has a trailing twelve months EPS of $-0.75.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.85%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 132% and a drop 10.5% for the next.

Moving Average

Travelzoo’s value is above its 50-day moving average of $5.16 and higher than its 200-day moving average of $5.39.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1%, now sitting on 65.65M for the twelve trailing months.

Yearly Top and Bottom Value

Travelzoo’s stock is valued at $5.64 at 17:32 EST, way under its 52-week high of $8.30 and way above its 52-week low of $4.10.

More news about Travelzoo.

4. Wheeler Real Estate Investment Trust (WHLRP) – -10.51%

Headquartered in Virginia Beach, VA, Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR ) is a fully integrated, self-managed commercial real estate investment company focused on owning and operating income-producing retail properties with a primary focus on grocery-anchored centers.

NASDAQ ended the session with Wheeler Real Estate Investment Trust falling 10.51% to $1.32 on Friday, following the last session’s downward trend. NASDAQ jumped 0.76% to $12,087.96, after three sequential sessions in a row of losses, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Wheeler Real Estate Investment Trust has a trailing twelve months EPS of $-1.868.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -6.81%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 73.6%, now sitting on 76.51M for the twelve trailing months.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Sep 26, 2018, the estimated forward annual dividend rate is 2.25 and the estimated forward annual dividend yield is 18.43%.

Yearly Top and Bottom Value

Wheeler Real Estate Investment Trust’s stock is valued at $1.32 at 17:32 EST, way under its 52-week high of $6.50 and above its 52-week low of $1.26.

More news about Wheeler Real Estate Investment Trust.

5. UTStarcom Holdings Corp (UTSI) – -7.59%

UTStarcom Holdings Corp. operates as a telecom infrastructure provider to develop technology for bandwidth from cloud-based services, mobile, streaming, and other applications in China, India, Japan, Taiwan, and internationally. The company's products include packet transport network, packet aggregation network, multi-services access network, fiber to the X, carrier Wi-Fi solutions, and software defined network controller products, as well as smart retail products. It serves telecommunications and cable service providers. The company was founded in 1991 and is based in Hangzhou, the People's Republic of China.

NASDAQ ended the session with UTStarcom Holdings Corp dropping 7.59% to $3.65 on Friday, after two consecutive sessions in a row of losses. NASDAQ rose 0.76% to $12,087.96, after three consecutive sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, UTStarcom Holdings Corp has a trailing twelve months EPS of $-0.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -11.33%.

Moving Average

UTStarcom Holdings Corp’s value is way under its 50-day moving average of $4.30 and under its 200-day moving average of $3.99.

More news about UTStarcom Holdings Corp.

6. Super Micro Computer (SMCI) – -6.79%

Super Micro Computer, Inc., together with its subsidiaries, develops and manufactures high-performance server and storage solutions based on modular and open architecture. Its solutions range from complete server, storage, modular blade servers, blades, workstations, full racks, networking devices, server management software, and server sub-systems, as well as security software. The company also provides application-optimized server solutions, including rackmount and blade servers, storage systems, and subsystems and accessories; and server software management solutions, such as Server Management Suite, including Supermicro Server Manager, Supermicro Power Management software, Supermicro Update Manager, SuperCloud Composer, and SuperDoctor 5. In addition, it offers server subsystems and accessories comprising server boards, chassis, power supplies, and other accessories. Further, the company provides server and storage system integration, configuration, and software upgrade and update services; and technical documentation services, as well as identifies service requirements, creates and executes project plans, and conducts verification testing and training services. Additionally, it offers help desk and on-site product support services for its server and storage systems; and customer support services, including ongoing maintenance and technical support for its products. The company provides its products to enterprise data centers, cloud computing, artificial intelligence, and 5G and edge computing markets. It sells its products through direct and indirect sales force, distributors, value-added resellers, system integrators, and original equipment manufacturers. The company primarily operates in the United States, Europe, Asia, and internationally. Super Micro Computer, Inc. was incorporated in 1993 and is headquartered in San Jose, California.

NASDAQ ended the session with Super Micro Computer falling 6.79% to $100.69 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Super Micro Computer has a trailing twelve months EPS of $1.64.

PE Ratio

Super Micro Computer has a trailing twelve months price to earnings ratio of 61.51. Meaning, the purchaser of the share is investing $61.51 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.49%.

Moving Average

Super Micro Computer’s worth is above its 50-day moving average of $92.57 and way above its 200-day moving average of $72.54.

Sales Growth

Super Micro Computer’s sales growth is 7.9% for the current quarter and negative 0.9% for the next.

More news about Super Micro Computer.

7. Vertex Energy (VTNR) – -6.59%

Vertex Energy, Inc., an environmental services company, provides a range of services designed to aggregate, process, and recycle industrial and commercial waste systems in the Gulf Coast and Central Midwest regions of the United States. The company operates in three segments: Black Oil, Refining and Marketing, and Recovery. The Black Oil segment collects and purchases used motor oil directly from third-party generators; aggregates used motor oil from a network of local and regional collectors; and sells used motor oil to customers for use as a feedstock or replacement fuel for industrial burners. It also produces and sells a vacuum gas oil product to refineries and marine fuels market; and base oil product to lubricant packagers and distributors. The Refining and Marketing segment gathers hydrocarbon streams in the form of petroleum distillates, transmix, and other chemical products that are purchased from pipeline operators, refineries, chemical processing facilities, and third-party providers; and sells end products, such as gasoline blendstock, pygas, and fuel oil cutter stock to oil companies or to petroleum trading and blending companies. The Recovery segment sells ferrous and non-ferrous recyclable metal products, and markets Group III base oils and other petroleum-based products, as well as provides transportation and marine salvage services. Vertex Energy, Inc. was founded in 2001 and is headquartered in Houston, Texas.

NASDAQ ended the session with Vertex Energy falling 6.59% to $8.36 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Vertex Energy has a trailing twelve months EPS of $-0.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -13.95%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 312.5% and 134.7%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1361.6%, now sitting on 2.79B for the twelve trailing months.

More news about Vertex Energy.

8. Aesthetic Medical International Holdings Group Ltd. (AIH) – -6.4%

Aesthetic Medical International Holdings Group Limited provides aesthetic medical services. It offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments comprising minimally invasive and energy-based treatments, including laser, ultrasound, and ultraviolet light treatments. The company also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. It operates 28 treatment centers in China, Hong Kong, and Singapore. The company was founded in 1997 and is headquartered in Shenzhen, China.

NASDAQ ended the session with Aesthetic Medical International Holdings Group Ltd. dropping 6.4% to $1.17 on Friday, following the last session’s downward trend. NASDAQ jumped 0.76% to $12,087.96, after three sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Aesthetic Medical International Holdings Group Ltd. has a trailing twelve months EPS of $-3.95.

Sales Growth

Aesthetic Medical International Holdings Group Ltd.’s sales growth is 1485.3% for the current quarter and 38.8% for the next.

More news about Aesthetic Medical International Holdings Group Ltd..

9. Applied Molecular Transport (AMTI) – -6.28%

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Applied Molecular Transport sliding 6.28% to $0.27 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Applied Molecular Transport has a trailing twelve months EPS of $-2.87.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -112.58%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 45.5% and 106.5%, respectively.

Moving Average

Applied Molecular Transport’s worth is way below its 50-day moving average of $0.49 and way under its 200-day moving average of $1.17.

More news about Applied Molecular Transport.

10. Verastem (VSTM) – -6.12%

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

NASDAQ ended the session with Verastem falling 6.12% to $0.40 on Friday while NASDAQ rose 0.76% to $12,087.96.

Earnings Per Share

As for profitability, Verastem has a trailing twelve months EPS of $-0.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -109.39%.

Volume

Today’s last reported volume for Verastem is 433573 which is 44.05% below its average volume of 775048.

Revenue Growth

Year-on-year quarterly revenue growth declined by 100%, now sitting on 2.6M for the twelve trailing months.

Moving Average

Verastem’s value is way below its 50-day moving average of $0.51 and way below its 200-day moving average of $0.71.

More news about Verastem.

Stay up to date with our winners and losers daily report